Study identifies two promising molecular targets for drug development in recurrent and metastatic cervical cancer
NRG Oncology GOG-0240 is the phase 3 randomized trial that demonstrated that the incorporation of bevacizumab with chemotherapy resulted in a statistically significant and clinically meaningful survival benefit for women ...
Mar 27, 2023
0
2